Longeveron Inc. develops regenerative cellular therapies centered on laromestrocel, also known as Lomecel-B, a proprietary allogeneic investigational cell therapy. The company’s clinical programs address hypoplastic left heart syndrome, Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging-related frailty.
Recurring news for LGVN covers clinical-trial safety reviews, FDA interactions and designations, intellectual-property updates for mesenchymal stem cell methods, financial results, private placements, and Nasdaq-related corporate matters. Updates often focus on the ELPIS II HLHS program, laromestrocel regulatory strategy, and financing used to support clinical development.
Longeveron (NASDAQ: LGVN) has retained Lucid Capital Markets as its financial advisor to explore potential strategic opportunities for the company. Those opportunities include a potential business combination; the engagement is exploratory.
Longeveron (NASDAQ: LGVN) reported updated ELPIS II Phase 2b results showing a statistically significant secondary endpoint for laromestrocel in infants with HLHS. The trial evaluated the investigational cell therapy alongside Stage II surgery in 40 infants with hypoplastic left heart syndrome, a congenital heart defect. Major adverse cardiac events numbered 8 with standard care versus 1 with laromestrocel (p=0.043).
The trial did not meet its primary endpoint of change in right ventricular ejection fraction, a measure of heart pumping function, at Month 12. Baseline and Month 12 imaging were available for 28 infants. Total major cardiac events numbered 22 versus 3 (p<0.001). No treatment-related serious adverse events were identified through 12 months. Longeveron intends to request an FDA meeting to review the results and determine potential next steps.
Longeveron (LGVN) will participate in three longevity and aging investment conferences while pursuing funding opportunities and reporting laromestrocel research findings. The October events are ARDD, Abundance Longevity Trip and Longevity Partnering Forum.
A new medRxiv preprint reports a post-hoc exploratory analysis of the randomized Phase 2a CLEAR MIND Alzheimer’s study involving 49 participants. Longeveron said the findings indicate laromestrocel may reduce brain inflammation. Reduced inflammation correlated with less brain atrophy and improved clinical scores; the analysis has not completed peer review.
Phase 2b frailty results showed improved physical condition after nine months versus placebo. Longeveron received a $1,000,000 XPRIZE Milestone 2 Award for a future competition clinical trial and intends to pursue funding and potential revenue opportunities to advance laromestrocel in longevity and aging-related frailty.
Longeveron (LGVN) reported topline results from the Phase 2b ELPIS II trial of laromestrocel in 40 infants with hypoplastic left heart syndrome, which did not meet its primary endpoint of improvement in right ventricular ejection fraction at Month 12.
In the intent-to-treat analysis, the least-squares mean difference in RVEF between treatment groups was −0.7 percentage points (95% CI: −7.3 to 5.9; p=0.8336). Exploratory as-treated outcomes showed no deaths over 12 months in laromestrocel-treated patients versus one in control, one transplant-free survival event out of 17 treated patients versus two out of 21 controls over up to five years, similar hospitalization burden, and 12 adjudicated MACE events in the treated arm versus 19 in the untreated arm, although this analysis and a sponsor-defined composite endpoint were not statistically significant.
Laromestrocel’s safety profile was generally consistent with prior experience in 644 treated participants, with no new safety signals and no treatment-emergent adverse events assessed as related. Longeveron will conduct further analyses, discuss the data with the FDA about potential next steps in HLHS, review all strategic options with an investment bank advisor, implement cash conservation measures, and seek funding and revenue opportunities to advance its longevity and Aging-related Frailty program, which has shown improved physical condition in a Phase 2b trial and yielded a $1,000,000 XPRIZE Healthspan Milestone 2 Award.
Longeveron (LGVN) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14–16, 2026.
The company’s presentation is scheduled for Monday, September 14, 2026, from 1:00–1:30 p.m. ET. A webcast of the presentation will be available via the “Events and Presentations” section of Longeveron’s website.
Longeveron (NASDAQ: LGVN) will implement a 1‑for‑10 reverse stock split of its Class A and Class B common stock, effective 11:59 p.m. ET on August 26, 2026. Split‑adjusted Class A shares will begin trading on August 27, 2026 under ticker LGVN and new CUSIP 54303L 302.
The reverse split, previously approved by stockholders and the board, is intended to help regain compliance with Nasdaq’s $1.00 minimum bid price. Outstanding Class A shares will decline from about 30.43 million to 3.04 million, and Class B from about 1.45 million to 144,901, with no change to authorized shares or par value. Fractional shares will be rounded up at the DTC participant level, and related warrants and equity awards will be proportionally adjusted.
Longeveron (NASDAQ: LGVN) appointed Nirav Jhaveri, CFA, as Chief Financial Officer, principal financial officer and principal accounting officer, joining the executive leadership team and succeeding Marie Washburn, who returns to her prior role as Corporate Controller.
According to Longeveron, Jhaveri brings over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector and prior CFO roles at Opus Genetics (Nasdaq: IRD), Insilico Medicine (HKEX: 3696.HK) and Journey Medical (Nasdaq: DERM). The company also highlighted ongoing development of its stem cell therapy laromestrocel, with top-line data from a Phase 2b trial in HLHS expected in September 2026.
Longeveron (NASDAQ: LGVN) reported 2026 second quarter revenue of $0.3 million, down 10% year over year, with gross profit of $0.2 million, up 25%. Net loss widened to $6.1 million from $5.0 million, driven by higher legal and clinical trial expenses. Cash and cash equivalents were $10.1 million at June 30, 2026, which the company expects will fund operations into the fourth quarter of 2026.
Top-line results from the Phase 2b ELPIS II trial of laromestrocel in hypoplastic left heart syndrome are anticipated in September 2026, following a Data Monitoring Committee review indicating no safety concerns. Longeveron was selected as a Finalist Team in the XPRIZE Healthspan competition and will receive a $1.0 million Milestone 2 award. Additional updates covered Alzheimer’s disease, aging-related frailty, pediatric dilated cardiomyopathy, patent grants, EMA SME status, and new independent directors.
Longeveron (NASDAQ: LGVN) has been selected from over 600 global applicants as a Milestone 2 Awardee and Finalist Team in the XPRIZE Healthspan competition. The company will receive a $1,000,000 Milestone 2 Award to fund its competition clinical trial of laromestrocel, an allogeneic mesenchymal stem cell therapy.
Longeveron’s selection was based on published clinical trial results in Aging-related Frailty showing increased 6-minute walk distance. Laromestrocel has shown positive initial data across 5 trials in 3 indications and has 5 related U.S. FDA designations and 52 issued patents worldwide.
Longeveron (NASDAQ: LGVN) will report its 2026 second quarter financial results and provide a business update on Wednesday, August 12, 2026, after U.S. markets close. The company will host a conference call and webcast at 4:30 p.m. ET, with dial-in 1.877.407.0789 and conference ID 13761959. An archived replay will be available on the Events & Presentations section of Longeveron’s website.